

Unaudited Financial Statements and Management's Discussion & Analysis

For the quarterly period ended August 31, 2025

BIOQUAL, INC.

Prepared by:

**Chris Kirk
Chief Financial Officer**

BIOQUAL, INC.

INDEX

<u>Financial Information</u>	<u>Page</u>
Financial Statements.	
Unaudited Balance Sheets, August 31, 2025 and May 31, 2025.....	2
Unaudited Statements of Operations for the Three Months Ended August 31, 2025 and August 31, 2024	3
Unaudited Statements of Stockholders' Equity for the Three Months Ended August 31, 2025 and August 31, 2024	4
Unaudited Statements of Cash Flows for the Three Months Ended August 31, 2025 and August 31, 2024	5
Management's Discussion and Analysis	6

BIOQUAL, INC.**UNAUDITED BALANCE SHEETS, AUGUST 31, 2025 AND MAY 31, 2025**

<u>ASSETS</u>	<u>August 31, 2025</u>	<u>May 31, 2025</u>
CURRENT ASSETS:		
Cash and cash equivalents	\$ 18,898,190	\$ 17,852,996
Accounts receivable:		
Trade	9,848,888	11,547,969
Unbilled – current	1,316,244	1,608,824
Prepaid expenses	293,350	296,042
Total current assets	<u>30,356,672</u>	<u>31,305,831</u>
PROPERTY AND EQUIPMENT:		
Leasehold improvements	12,059,053	12,059,053
Furniture, fixtures and equipment	19,399,708	19,399,708
Total	<u>31,458,761</u>	<u>31,458,761</u>
Less accumulated depreciation and amortization	<u>(23,282,983)</u>	<u>(22,716,754)</u>
Property and equipment, net	<u>8,175,778</u>	<u>8,742,007</u>
OTHER ASSETS:		
Security deposits	18,551	18,551
Goodwill	1,028,408	1,028,408
Operating lease right-of-use assets	14,543,814	15,510,448
Deferred income tax asset	512,900	512,900
Total other assets	<u>16,103,673</u>	<u>17,070,307</u>
TOTAL	<u>\$ 54,636,123</u>	<u>\$ 57,118,145</u>
<u>LIABILITIES</u>		
CURRENT LIABILITIES:		
Accounts payable	\$ 1,437,755	\$ 1,897,407
Accrued compensation and related liabilities	942,481	1,788,432
Operating lease liabilities, current	4,008,678	3,993,044
Deferred revenue	795,208	737,142
Total current liabilities	<u>7,184,122</u>	<u>8,416,025</u>
Deferred income taxes	-	-
Operating lease liabilities, non-current	<u>11,546,304</u>	<u>12,547,591</u>
Total liabilities	<u>18,730,426</u>	<u>20,963,616</u>
<u>STOCKHOLDERS' EQUITY</u>		
Preferred stock - par value of \$1.00 per share; 500,000 shares authorized; no shares issued and outstanding		
Common stock - par value of \$.01 per share; 5,000,000 shares authorized; 1,599,408 shares issued; 894,416 shares outstanding	15,994	15,994
Additional paid-in capital	7,364,934	7,364,934
Retained earnings	29,566,009	29,814,841
Treasury stock, at cost	<u>(1,041,240)</u>	<u>(1,041,240)</u>
Total stockholders' equity	<u>35,905,697</u>	<u>36,154,529</u>
TOTAL	<u>\$ 54,636,123</u>	<u>\$ 57,118,145</u>

See Management's Discussion and Analysis.

BIOQUAL, INC.
 UNAUDITED STATEMENTS OF OPERATIONS
 FOR THE THREE MONTHS ENDED AUGUST 31, 2025 AND AUGUST 31, 2024

	<u>2025</u>	<u>2024</u>
REVENUES:		
Contract revenues	\$ <u>9,855,399</u>	\$ <u>11,770,482</u>
Total Revenues	<u>9,855,399</u>	<u>11,770,482</u>
OPERATING EXPENSES:		
Contract	8,979,805	11,333,204
General and administrative	<u>1,394,366</u>	<u>1,568,877</u>
Total Operating Expenses	<u>10,374,171</u>	<u>12,902,081</u>
OPERATING LOSS	(518,772)	(1,131,599)
INTEREST INCOME	<u>175,340</u>	<u>199,774</u>
LOSS BEFORE INCOME TAXES	(343,432)	(931,825)
BENEFIT FOR INCOME TAXES	<u>(94,600)</u>	<u>(256,500)</u>
NET LOSS	<u>\$ (248,832)</u>	<u>\$ (675,325)</u>
BASIC EARNINGS PER SHARE	\$ (0.28)	\$ (0.76)
DILUTED EARNINGS PER SHARE	<u>\$ (0.28)</u>	<u>\$ (0.76)</u>
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING FOR BASIC EARNINGS PER SHARE	894,416	894,416
EFFECT OF DILUTIVE SECURITIES – OPTIONS WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING FOR DILUTED EARNINGS PER SHARE	<u>(427)</u>	<u>(11)</u>
	<u>893,989</u>	<u>894,405</u>

See Management's Discussion and Analysis.

BIOQUAL, Inc.**Unaudited Statements of Stockholders' Equity**

	Common Stock		Treasury Stock		Additional Paid-In Capital	Retained Earnings	Total
	Shares	Amount	Shares	Amount			
Balance, June 1, 2025	1,599,408	\$ 15,994	704,992	\$ (1,041,240)	\$ 7,364,934	\$ 29,814,841	\$ 36,154,529
Net Loss	-	-	-	-	-	(248,832)	(248,832)
Balance August 31, 2025	1,599,408	\$ 15,994	704,992	\$ (1,041,240)	\$ 7,364,934	\$ 29,566,009	\$ 35,905,697

	Common Stock		Treasury Stock		Additional Paid-In Capital	Retained Earnings	Total
	Shares	Amount	Shares	Amount			
Balance, June 1, 2024	1,599,408	\$ 15,994	704,992	\$ (1,041,240)	\$ 7,364,934	\$ 31,310,203	\$ 37,649,891
Net Loss	-	-	-	-	-	(675,325)	(675,325)
Balance August 31, 2024	1,599,408	\$ 15,994	704,992	\$ (1,041,240)	\$ 7,364,934	\$ 30,634,878	\$ 36,974,566

See Management's Discussion and Analysis.

BIOQUAL, INC.
UNAUDITED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED AUGUST 31, 2025 AND AUGUST 31, 2024

	<u>2025</u>	<u>2024</u>
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (248,832)	\$ (675,325)
Adjustments to reconcile net income to net cash provided by (used by) operating activities:		
Depreciation and amortization	566,229	619,464
Amortization of operating lease right-of-use asset	966,634	957,040
(Increase) decrease in		
Accounts receivable	1,991,661	330,396
Prepaid expenses	2,692	(527,686)
Increase (decrease) in		
Accounts payable	(459,652)	49,349
Accrued compensation and related liabilities	(845,951)	(1,125,605)
Operating lease liabilities	(985,653)	(991,398)
Deferred revenue	58,066	(9,087)
NET CASH PROVIDED BY (USED BY) OPERATING ACTIVITIES	<u>1,045,194</u>	<u>(1,372,852)</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchases of property and equipment	-	(187,621)
NET CASH USED BY INVESTING ACTIVITIES	<u>-</u>	<u>(187,621)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Dividend paid	-	-
NET CASH USED BY FINANCING ACTIVITIES	<u>-</u>	<u>-</u>
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	1,045,194	(1,560,473)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	17,852,996	15,594,090
CASH AND CASH EQUIVALENTS AT END OF PERIOD	<u>\$ 18,898,190</u>	<u>\$ 14,033,617</u>

See Management's Discussion and Analysis.

MANAGEMENT'S DISCUSSION AND ANALYSIS

Interim Financial Statements

In the opinion of management, all adjustments consisting only of normal recurring accruals necessary for a fair presentation of such amounts have been included. The results of operations for the quarter are not necessarily indicative of results for the year.

Items of Note

In the first quarter of fiscal year 2026, which commenced on June 1, 2025, the Company realized a net loss of \$248,832 compared to a net loss of \$675,325 for the first quarter of fiscal year 2025. See Results of Operations below for more detail on the change.

Subsequent to the end of the first quarter of fiscal year 2026, the National Institute of Allergy and Infectious Diseases (NIAID) provided \$9,437,520 of funding for the sixth option year of the contract entitled "Animal Care and Laboratory Support Services to the Vaccine Research Center". The seven-year contract has a maximum potential funding amount of \$69,174,672 including all options. The cumulative funding of the contract increased from \$51,463,086 to \$60,900,606. The funding covers costs incurred from September 28, 2025, through September 27, 2026, which is the final year of contract.

Results of Operations

Three Months Comparison

The \$1,915,083 decrease in revenues to \$9,855,399 for the quarter ended August 31, 2025, compared to \$11,770,482 for the quarter ended August 31, 2024, is primarily the result of a decrease in contract activity in commercial contracts of approximately \$1,519,000 compared to the first quarter of the previous fiscal year due to the significant decrease in COVID related work. In addition, there was a decrease in revenue from government contracts of approximately \$324,000, as well as a decrease in revenue from grants of approximately \$71,000 compared to the first quarter of the previous fiscal year.

The \$2,353,399 decrease in Contract expenses for the quarter ended August 31, 2025, primarily reflects decreases in labor and labor-related costs due to the reduction in staff that occurred during FY25, as well as reductions in animal procurement and materials and supplies due to the decrease in the volume of work.

The \$174,511 decrease in General and Administrative (G&A) expenses for the quarter ended August 31, 2025, primarily reflects decreases in labor and labor-related costs compared to similar costs incurred in the first quarter of the previous fiscal year.

The \$612,827 decrease in operating loss primarily reflects the reduction in costs mentioned above.

Liquidity and Capital Resources

During the first three months of fiscal year 2026, the Company made no capital expenditures compared to approximately \$188,000 in the first three months of fiscal year 2025. The Company has

been able to continue to fund all capital expenditures through the use of available cash.

During the next nine months, the Company estimates the aggregate purchase price of equipment to upgrade older equipment, enhance its capabilities, and to renovate animal housing space will total approximately \$1,000,000.

The Company is obligated, as lessee, under non-cancellable operating leases covering its facilities and certain equipment at various dates through 2031. Operating lease costs for the first three months of fiscal year 2026 were approximately \$1,189,000. As of August 31, 2025, the total lease payments are approximately \$17,545,000 through 2031.

Other than the items mentioned above, the Company does not anticipate other substantial capital and other expenditures during fiscal year 2026. However, if the Company is awarded new contracts or adds capabilities to enable it to serve markets that it doesn't currently serve that require additional equipment or animal enclosures during that period, the Company believes it will have sufficient capital resources to provide for the purchase of the equipment.

BIOQUAL has a \$2,000,000 line of credit with M&T Bank available to help cover costs of its daily operations. The line of credit is due on demand and renewable annually. As of August 31, 2025, there was no balance due on the line of credit. The interest rate on funds drawn on the line of credit is the prime rate plus .25%, which as of August 31, 2025, was 7.75%. On August 31, 2025, the Company had a balance of cash and cash equivalents of \$18,898,190. With the above line of credit and the cash resources expected to be available as a result of collection of accounts receivable, the Company believes it will have sufficient capital resources to provide for daily operations and its capital needs through the end of fiscal year 2026.

The following provides additional information on select balance sheet items: 1) the \$1,699,081 decrease in trade accounts receivable primarily is the result of the impact of the decrease in billings for the quarter; 2) the \$845,951 decrease in accrued compensation and related liabilities reflects the payment of the May 31, 2025 accrued payroll, fiscal year 2025 bonuses, and severance related to the FY25 reduction in force; 3) the \$292,580 decrease in unbilled receivables primarily is the result of prebilling in the first three months of the fiscal year; and 4) the \$459,652 decrease in accounts payable during the first quarter of fiscal year 2025 primarily is the result of the reduced volume of work in the first quarter.

Notes to financial statements

Risks and uncertainties

The future of the Company's revenue in the context of recently reduced government funding hinges on several factors, including the eventual establishment of a formal strategic plan by NIH and possible policy shifts based on emerging infectious diseases. The current Administration has eliminated certain funding opportunities for vaccine related projects, especially those relating to the mRNA vaccine platform and COVID-19 related research. Extramural grants to academic laboratories and BARDA funded contracts have also been targeted for cancellation by the government. A formal strategic plan for the NIH research priorities beyond FY25 has not yet been made available by the new Administration. This hampers our ability to predict the extent to which the Company's revenue will be affected during the upcoming years under the current Administration. Based on the events described above, the Company recognizes that the amount of funds available for the type of work

done by the Company is likely to remain reduced in the medium term. The Company is working to adapt to the new funding situation and intends to continue to reduce its costs in order to achieve profitability. Continuous monitoring of policy changes and proactive adjustments to research strategies will be crucial for the Company in navigating the evolving landscape of biomedical research funding.

Leases

The Company enters into leases as a lessee for certain buildings and equipment. The Company's leases typically have lease terms between three years and ten years and may include one or more renewal options. Under Accounting Standards Codification (ASC) Topic 842, *Leases*, at contract inception the Company determines whether a contract is or contains a lease and whether the lease should be classified as an operating or finance lease. Operating lease balances are included in the operating lease right-of-use assets and operating lease liabilities in the accompanying Balance Sheets for the quarter ended August 31, 2025, and the year ended May 31, 2025.

The Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of the future minimum lease payments over the lease term at the commencement date. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of future payments and the appropriate lease classification. Many of the Company's leases include renewal options aligned with any extended lease contract terms. The Company defines the initial lease term to include renewal options determined to be reasonably certain. When the Company adopted ASC 842, it elected, as allowed by the standard, not to recognize a right-of-use asset and a lease liability for leases with an initial term of 12 months or less; it recognizes lease expense for these leases on a straight-line basis over the lease term. The Company also elected not to separate lease components from non-lease components and applied this to all material classes of leased assets.

Finance leases are not material to the Company's financial statements, and the Company is not a lessor in any material arrangements. The Company does not have any material restrictions or covenants in the lease agreements, sale-leaseback transactions, land easements or residual value guarantees.

The components of total lease cost and other supplemental lease information are presented in the following tables:

	<u>For the Three Months Ended</u> <u>August 31, 2025</u>
Components of lease cost:	
Operating lease costs	\$ 1,188,712
Cash paid for amounts included in the measurement of lease liabilities	
Operating cash flows from operating leases	\$ 1,206,549

Weighted average remaining lease terms and discount rates are presented in the following table:

	<u>August 31, 2025</u>
Weighted average remaining lease term (in years):	
Operating leases	4.14
Weighted average discount rate (annual):	
Operating leases	5.51%

The following table presents a maturity analysis of the Company's operating liabilities at August 31, 2025

	<u>Operating Leases</u>
2026	\$ 4,764,887
2027	4,484,156
2028	3,221,564
2029	2,711,221
2030	1,403,574
Thereafter	959,365
Total lease payments	17,544,767
Less: imputed interest	(1,989,785)
Present value of lease liabilities	<u>\$ 15,554,982</u>

Revenue recognition accounting

Billings under cost-based government contracts are calculated using provisional rates which permit recovery of indirect costs. These rates are subject to audit on an annual basis by the government agencies' cognizant audit agency. The cost audits will result in the negotiation and determination of the final indirect cost rates which the Company may use for the years audited. The final rates, if different from the provisional rates, may create a receivable or a liability.

As of August 31, 2025, the Company had negotiated final settlements on indirect cost rates through May 2024. The Company periodically reviews its cost estimates and experience rates. Adjustments, if needed, are made and reflected in the period in which the estimates are revised. In the opinion of management, redetermination of any cost-based contracts for the open years will not have any material effect on the Company's financial position or results of operations.

Changes in estimates related to contracts with performance obligation(s) accounted for using the output method on fixed-price-milestone (FP-M) type contracts, that is primarily based on a proportion of study-related procedures and/or tests, are recognized in the period in which such changes are made on a cumulative catch-up basis. This basis recognizes in the current period the cumulative effect of the changes on current and prior periods based on the performance obligations related proportionate progress towards completion.

For the three months ended August 31, 2025, there were no material modifications recorded related to work previously performed on FP-M type contracts prior to the execution of formal modifications or amendments. A significant change in one or more estimates could affect the profitability of one or more of the performance obligations.

Remaining Performance Obligations: Remaining performance obligations represent the expected value (transaction price) of executed contracts, both funded and unfunded, less revenue recognized to date. Remaining performance obligations do not include future potential purchase or work orders expected to be awarded under Master Service Agreement (MSA) or similar agreements.

As of August 31, 2025, the Company expects to recognize a majority of the remaining performance obligations over the next 12 months.

Disaggregation of Revenues: The Company disaggregates revenue by customer-type and contract-type as these categories best represent how the nature, timing and uncertainty of the Company's revenue and cash flows are affected by the U.S. government procurement environment and other economic factors.

Disaggregated revenue by customer-type and contract type was as follows:

Disaggregated revenue:

Revenue by Customer Type and Contract Type	Three Months Ended August 31, 2025
National Institutes of Health (NIH)	
Cost-Plus-Fixed-Fee	\$ 2,686,513
Total National Institutes of Health	<u>2,686,513</u>
Commercial and Other	
Fixed-Price-Per-Unit and Time-And-Materials	6,392,982
Fixed-Price-Milestone	<u>775,904</u>
Total Commercial and Other	<u>7,168,886</u>
Total Revenues	<u>\$ 9,855,399</u>

Cost-plus-fixed-fee (CPFF) contracts are generally lower risk and have lower profits. Time-and-materials (T&M) and fixed-price-per-unit (FP-U) contracts are also low risk, but profits may vary depending on actual labor costs compared to negotiated contract billing rates. Fixed-price-milestone (FP-M) contracts offer the potential for higher profits while increasing the Company's exposure to risk of cost overruns.

Contract Assets and Liabilities: Contract assets include unbilled contract receivables, which is the amount of revenue recognized that exceeds the amount billed to the customer, and right to payment is not just subject to the passage of time. Contract assets also include incremental fulfillment costs where, under certain fixed-price contracts, costs are usually incurred at the beginning of the contract performance, where the single performance obligation has not yet been completely satisfied. Contract liabilities consist of deferred revenue.

The components of contract assets and contract liabilities consisted of the following:

Contract asset and liabilities:

		<u>August 31,</u> <u>2025</u>	<u>June 1,</u> <u>2025</u>
Contract assets:	Balance sheet line item:		
Unbilled contract receivables ⁽¹⁾	Accounts receivable	\$ 1,316,244	\$ 1,608,824
Fulfillment costs	Prepaid expenses	7,900	7,900
		<u>\$ 1,324,144</u>	<u>\$ 1,616,724</u>
Contract liabilities:	Balance sheet line item:		
Deferred revenue	Deferred revenue	<u>\$ 795,208</u>	<u>\$ 737,142</u>

The increase in "Contract liabilities- current" was primarily due to prebilling in the first quarter of the fiscal year.

During the three months ended August 31, 2025, the Company recognized revenue of approximately \$119,000 relating to amounts that were included as a contract liability at June 1, 2025.

During the three months ended August 31, 2025, the Company did not recognize any amortization related to its fulfillment costs. The Company did not recognize any impairment losses on contract assets for the three months ended August 31, 2025.

- ⁽¹⁾ Balances include primarily timing differences between what the Company has billed or has the right to bill as of the period end as compared with the revenue recognized, on FP-M and CPFF type contracts.

Forward Looking Information

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and one should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company's ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company's ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company's ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company's contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

BIOQUAL, Inc.

A Delaware Corporation

9620 Medical Center Dr., Suite 310

Rockville, MD 20850

240-404-7654

www.bioqual.com

irinfo@bioqual.com

SIC Code: 8731 - Commercial Physical and Biological Research

Quarterly Report

For the Period Ending: August 31, 2025

As of August 31, 2025, the current reporting period date, the number of shares outstanding of our Common Stock was:

894,416

As of May 31, 2025, the prior quarter period end date, the number of shares outstanding of our Common Stock was:

894,416

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934): Yes No

Indicate by check mark whether the company's shell status has changed since the previous reporting period: Yes No

Indicate by check mark whether a Change in Control of the company has occurred over this reporting period: Yes No

BIOQUAL, Inc.

Information and Disclosure for the quarter ended August 31, 2025

The Company voluntarily reports information through the OTC Markets platform. This disclosure statement (“Disclosure Statement”) constitutes part of the Company’s voluntary reporting and should be read in conjunction with other filings by the Company.

FORWARD LOOKING STATEMENTS

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and one should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

1) Name of the issuer and its predecessors (if any)

BIOQUAL, Inc., prior to January 1, 2000, known as Diagnon Corporation.

BIOQUAL, Inc. was incorporated on June 15, 1981, in the state of Delaware. BIOQUAL's current standing in the state of Delaware is active.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception: None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: None

The address of the issuer's principal executive office:

BIOQUAL, Inc.
9600 Medical Center Dr., Suite 101
Rockville, MD 20850

The addresses of the issuer's principal place of business:

BIOQUAL, Inc.
9600 Medical Center Dr., Suite 101
Rockville, MD 20850

BIOQUAL, Inc.
12301 Parklawn Dr.
Rockville, MD 20852

BIOQUAL, Inc.
2501 Research Blvd.
Rockville, MD 20850

BIOQUAL, Inc.
1330 Piccard Dr., Suite 202
Rockville, MD 20850

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years: Yes No

2) Security Information

Transfer Agent

Computershare, Inc.
1-800-305-9404
www.computershare.com
P.O. Box 43078
Providence, RI 02940

Trading Symbol: BIOQ
Exact title and class of securities outstanding: Common Stock
CUSIP: 09065J101
Par or Stated Value: \$.01
Total shares authorized: 5,000,000 as of August 31, 2025
Total shares outstanding: 894,416 as of August 31, 2025
Total number of shareholders of record: 139 as of August 31, 2025

Security Description:

1. Common equity dividend, voting and preemption rights.

Dividends - Each share of Common Stock issued and outstanding shall be identical in all respects one with the other, and no dividends shall be paid on any shares of Common Stock unless the same dividend is paid on all shares of Common Stock outstanding at the time of such payment.

Voting – Each holder of Common Stock shall be entitled to one vote for each share of Common Stock held on all matters as to which holders of Common Stock shall be entitled to vote.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions. N/A
3. Describe any other material rights of common or preferred stockholders. N/A
4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report. N/A

3) Issuance History

A. Changes to the Number of Outstanding Shares

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any subsequent interim period.

On August 27, 2020, the Company's Board of Directors adopted the Company's 2020 Stock Incentive Plan (the "2020 Plan"). The purpose of the 2020 Plan is to provide an incentive to attract and retain directors, officers, consultants, advisors, and employees whose services are considered valuable, to encourage a sense of proprietorship, and to stimulate an active interest of these persons in the Company's development and financial success. Under the 2020 Plan, the Company was authorized to issue up to 500,000 shares of Common Stock, including incentive stock options intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended, non-qualified stock options, stock appreciation rights ("SARs"), performance shares, restricted stock, and long-term incentive awards. The 2020 Plan was approved by the Company's shareholders at the Annual Meeting of Shareholders on October 21, 2020.

On November 25, 2020, the Board determined that it would be in the best interest of the Company's shareholders and therefore resolved to amend the Stock Incentive Plan by reducing the number of shares that may be issued pursuant to the Plan from 500,000 to 180,000 shares of the Company's common stock and to increase the percentage of shares that may be issued as Incentive Stock Options from 5 percent of the then issued and outstanding common stock of the Company to 20 percent of such common stock. The amendments described above were approved by a majority of the Company's shareholders at the Annual Meeting of Shareholders held on October 27, 2021.

Check to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: X

B. Promissory and Convertible Notes

Check if there are no outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities: X

4) Issuer's Business, Products and Services

A. Description of the issuer's business operations:

BIOQUAL, Inc., formerly Diagon Corporation (the "Company" or "BIOQUAL"), was founded in 1981 to develop, produce and sell diagnostic test kits incorporating monoclonal antibodies to diagnose certain anemias, infections, and parasitic diseases. In fiscal year 1988, the Company discontinued the diagnostic test kit segment of its business to concentrate on and to expand its contract research base with the National Institutes of Health (NIH).

On December 31, 1999, Diagon Corporation ("Diagon") changed its name to BIOQUAL, Inc. The name change was effected as a result of the merger of Diagon and its wholly - owned subsidiary, BIOQUAL, Inc., with Diagon being the surviving

corporation. In the merger, Diagon adopted the name BIOQUAL, Inc. as the name of the surviving entity.

The Company currently performs contract research services primarily focused on animal models of human diseases including AIDS, influenza, Respiratory Syncytial Virus (RSV) infection, Coronavirus infections (including COVID-19), Flavivirus infections (including Zika and Dengue), malaria, hepatitis, cancer, and other emerging infectious diseases. The Company is actively involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies.

B. List any subsidiaries, parent company, or affiliated companies: None

C. Describe the issuer’s principal products or services:

The Company currently performs contract research services primarily focused on animal models of human diseases including AIDS, influenza, RSV infection, Coronavirus infections (including COVID-19), Flavivirus infections (including Zika and Dengue), malaria, hepatitis, cancer, and other emerging infectious diseases. The Company also performs *in vitro* contract research services. The Company is actively involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company provides its services to the federal government, universities and the life science and pharmaceutical industries.

5) Describe the Issuer’s Facilities

The Company currently leases space in five facilities in Rockville, Maryland, totaling 160,620 square feet. Approximately 129,712 square feet of space used as a vivarium, approximately 21,492 square feet operates as an *In Vitro* laboratory, and the balance (9,416 square feet) serves as office space for the Corporate Headquarters. The Company maintains the condition of its facilities so that each facility is adequate for the performance of the Company’s current contractual obligations.

Lease details as of August 31, 2024, for each facility are listed below:

<u>Street Address</u>	<u>City, State</u>	<u>Square Feet</u>	<u>Expiration Date</u>	<u>Options</u>
9620 Medical Center Dr. (Corporate HQ offices)	Rockville, MD	9,416	10/31/2027	5 years
9600 Medical Center Dr. (Labs and Vivarium)	Rockville, MD	37,274	10/31/2027	5 years
12301 Parklawn Dr. (Vivarium)	Rockville, MD	49,185	5/31/2029	none
2501 Research Blvd. (Vivarium)	Rockville, MD	30,000	5/31/2027	5 years
1330 Piccard Dr. (Vivarium)	Rockville, MD	34,745	4/30/2031	5 years

During the first three months of fiscal year 2026, the Company made no capital expenditures compared to approximately \$188,000 in the first three months of fiscal year 2025. The Company has been able to continue to fund all capital expenditures through the use of available cash.

During the next nine months, the Company estimates the aggregate purchase price of equipment to upgrade older equipment, enhance its capabilities, and to renovate animal housing space will total approximately \$1,000,000.

6) Officers, Directors, and Control Persons

A. Names of Officers, Directors, and Control Persons:

Name of Officer/Director and Control Person	Affiliation with Company	Residential Address	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Notes
Mark G. Lewis	Chairman of the Board	Arlington, VA	1,000	Common	0.11%	
Merrywitch Investment, LLC	Thomas August, Deceased Former Director, Control Person		177,339	Common	19.83%	Company set up by family of Thomas August, Former Director
Amy McPhaul Johnston	Director	York, PA	0	Common	0%	
Charles F. Gauvin	Director	New Gloucester, ME	2,167	Common	0.24%	
David B. Landon	Director	Walpole, MA	3,665	Common	0.41%	David B. Landon is the son of John C. Landon, Deceased Former Chairman of the Board, CEO, and President of BIOQUAL
Vivek Shinde Patil	Director	Arlington, VA	0	Common	0%	
Mitchell L. Franklin	Chief Operating Officer, Secretary	Germantown, MD	0	Common	0%	
Charles C. Kirk, Jr	Chief Financial Officer	Silver Spring, MD	0	Common	0%	
Hanne A. Elyard	President and Chief Scientific Officer	Poolesville, MD	0	Common	0%	
David A. Newcomer	Director	Germantown, MD	2,718	Common	0.30%	
Lancatske LLC	John Landon, Former Chairman of the Board, CEO, President, and Control Person		155,764	Common	17.42%	Company set up by family of John Landon, Former Chairman of the Board, CEO, and President
Thomas A. Satterfield, Jr.	Control Person	Mountain Brook, AL	343,689	Common	38.43%	

7). Legal/Disciplinary History

A. None of the forgoing persons have, in the past ten years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended, or vacated, by a court of competent jurisdiction that permanently

or temporarily enjoined, barred, suspended, or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or
 4. A regulatory complaint or proceeding that could result in a "yes" answer to part 3 above: or
 5. The entry of an order by self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities; or
 6. A U.S. Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S. mail.
- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None.

8) **Third Party Service Providers**

Please provide the name, address, telephone number and email address of each of the following outside providers.

Securities Counsel

Ernest M. Stern, Esq.

Andrew E. Mishkin, Esq.

CM Law PLLC

1701 Pennsylvania Ave NW, Suite 200

Washington, DC 20006

Phone: (202) 255-0873

Email addresses: amishkin@cm.law; estern@cm.law

Accountant or Auditor

David H. Semendinger, CPA
Aprio, LLP
111 Rockville Pike, Suite 600
Rockville, MD 20850
Phone: 301-231-6200
Email address: david.semendinger@aprio.com

Investor Relations Consultant

None

Other Service Providers

None

9) Financial Statements

A. This Disclosure Statement was prepared by:

Charles C. Kirk, Jr, C.P.A.
Chief Financial Officer of issuer

B. The following financial statements were prepared in accordance with U.S. GAAP.

C. The financial statements for this reporting period were prepared by:

Charles C. Kirk, Jr, C.P.A.
Chief Financial Officer of issuer

10) Issuer Certification

Principal Executive Officer

I, Hanne Elyard Andersen, President, and Chief Scientific Officer, certify that:

1. I have reviewed this Disclosure Statement for BIOQUAL, Inc.;
2. Based on my knowledge, this Disclosure Statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Disclosure Statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this Disclosure Statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this Disclosure Statement.

/s/ Hanne E. Andersen
President and CSO

Date: October 21, 2025

Principal Financial Officer

I, Charles C. Kirk, Jr., Chief Financial Officer, certify that:

1. I have reviewed this Disclosure Statement for BIOQUAL, Inc.;
2. Based on my knowledge, this Disclosure Statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Disclosure Statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this Disclosure Statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this Disclosure Statement.

/s/ Charles C. Kirk, Jr.
Chief Financial Officer

Date: October 21, 2025